At the IGTP TODAY

News

17/06/2019 - Research

A new tool that makes it possible to adapt treatment for patients with cardiogenic shock has been discovered

Cardiogenic shock is a possible complication of serious heart attack involving an associated mortality rate of approximately 50% of all cases. The combination of this new tool with existing methods renders precise and patient-specific decision-making possible. The research is being led by Dr. Antoni Bayés at Germans Trias and the Proteomics Unit of the CRG and UPF, under Dr. Eduard Sabidó

Manremyc opens a funding round of 250,000 euros through the Capital Cell platform

Manremyc, a spin-off of the IGTP specialised in the development of a probiotic against tuberculosis, has opened a funding round through Capital Cell, the first on-line investment platform in Europe specialized in biomedicine. The objective of the campaign is to reach 250,000 euros, with a minimum investment requirement per person of only 600 euros. Up to now, the company has secured 35% of the investment, which includes participation from the Reig family, main shareholders in the pharmaceutical company Reig Jofre.

Events